ClinicalTrials.gg
Not yet recruitingNCT07695948Updated Jul 13, 2026

Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer Survivors

A Phase 3 interventional study of Acupuncture and Sham acupuncture in Breast Cancer, sponsored by University of Illinois at Chicago. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by University of Illinois at Chicago · Phase 3, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Breast Neoplasms by University of Illinois at Chicago — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · University of Illinois at Chicago.

Planned enrollment
3rd of 15
252 · median 46
Started
2026
with 2 others
Phase 3
2 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Breast Neoplasms by University of Illinois at Chicago, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 3, and was the 15th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 15 studies in Breast Neoplasms by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Breast Neoplasms by University of Illinois at Chicago, or all of them as a file.
02

Study summary

The purpose of this study is to examine the effect, mediators and predictors of treatment response of acupuncture in treating the psychoneurological symptom cluster (pain, fatigue, sleep disturbance) among breast cancer survivors.

Read the detailed description

Aim 1: compared to sham acupuncture and UC, determine the effect of acupuncture on a) the psychoneurological cluster (primary outcome) and b) pain, fatigue, and sleep disturbance as individual symptoms (secondary outcomes).

Aim 2: examine the role of methylsulfonylmethane as mediator in the mechanisms of acupuncture on the psychoneurological cluster and each individual symptom from week 0 to week 6 (primary endpoint) and to week 12 (secondary endpoint).

Aim 3: identify multilevel predictors of treatment response in the acupuncture group, including a) biological (metabolomic signature, age); 2) clinical (previous treatment) and 3) psychosocial (treatment expectancy) characteristics.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age
  • With confirmed Stage 0-III ER/PR-positive -negative breast cancer
  • Currently receiving endocrine therapy
  • Completed their primary cancer treatment (e.g., surgery, radiotherapy, chemotherapy) at least 3 months prior to recruitment
  • Acupuncture-naïve
  • Have self- reported pain, fatigue, and sleep disturbance in the last month with an average severity rating ≥ 3 (0-10 numeric rating scale) for at least 2 of the 3 symptoms.

Exclusion criteria

Exclusion Criteria:

  • Taking methylsulfonylmethane or glutathione supplements
  • Physically or cognitively unable to complete the study procedures
  • Pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Acupuncture group

    Behavioral: Acupuncture

  • Sham comparator
    Sham acupuncture group

    Behavioral: Sham acupuncture

  • No intervention
    Usual care group

    Participants will continue to receive their usual care.

Interventions

  • BehavioralAcupuncture

    All participants will receive a semi-standardized acupuncture protocol with needle penetrating to the skin. Participants will receive 2 acupuncture treatments each week for 5 weeks, for a total of 10 treatments. Each acupuncture treatment will take 30 minutes.

  • BehavioralSham acupuncture

    Participants will receive no-touch control needle on non- acupuncture points, with the tip that does not contact the skin. Participants will receive 2 sham acupuncture treatments each week for 5 weeks, for a total of 10 treatments. Each sham acupuncture treatment will take 30 minutes.

06

What researchers measure

Primary outcomes

  1. The psychoneurological symptom cluster

    Psychoneurological symptom cluster: The psychoneurological symptom cluster will be calculated as the mean of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 T-scores for Pain Interference, Fatigue, and Sleep Disturbance. Each domain is scored as a standardized T-score (approximate range 20-80), with higher scores indicating worse symptom severity. Higher composite scores indicate greater psychoneurological symptom burden.

    Time frame: week 0, week 6, week 12, week 24

Secondary outcomes

  1. PROMIS Pain Interference

    Scores range from 4-20; higher scores indicate that pain is interfering with daily activities more

    Time frame: week 0, week 6, week 12, week 24

  2. PROMIS fatigue

    Scores range from 4-20; higher scores indicate that severe fatigue

    Time frame: week 0, week 6, week 12, week 24

  3. PROMIS sleep disturbance

    Scores range from 4-20; higher scores indicate that severe sleep disturbance

    Time frame: Scores range from 4-20; higher scores indicate that severe fatigue

  4. Serum methylsulfonylmethane concentration

    Change in serum methylsulfonylmethane concentration.

    Time frame: week 0, week 6, week 12

  5. GSH/GSSG

    The ratio of glutathione and oxidized glutathione

    Time frame: week 0, week 6, week 12

07

Study locations

1 site
  • University of Illinois Chicago College of Nursing,
    Chicago, Illinois 60612, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2031, 59 months later.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 59 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2026
First posted
Jul 10, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Aug 31, 2031
CompletionEst.
Aug 31, 2031
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07695948
Responsible party
Hongjin Li (Associate Professor, University of Illinois at Chicago) — Principal investigator
First posted
Jul 10, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Aug 31, 2031 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Jul 13, 2026

Study contacts

Hongjin Li, PhD, RN, FAAN
Contact
hongjin@uic.edu
312-413-9845

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion